Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.52
JAZZ's Cash-to-Debt is ranked lower than
87% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. JAZZ: 0.52 )
Ranked among companies with meaningful Cash-to-Debt only.
JAZZ' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.13  Med: 0.67 Max: No Debt
Current: 0.52
0.13
No Debt
Equity-to-Asset 0.53
JAZZ's Equity-to-Asset is ranked lower than
67% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. JAZZ: 0.53 )
Ranked among companies with meaningful Equity-to-Asset only.
JAZZ' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.82  Med: 0.4 Max: 0.76
Current: 0.53
-0.82
0.76
Debt-to-Equity 0.58
JAZZ's Debt-to-Equity is ranked lower than
70% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. JAZZ: 0.58 )
Ranked among companies with meaningful Debt-to-Equity only.
JAZZ' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.71  Med: 0.58 Max: 1.57
Current: 0.58
-1.71
1.57
Debt-to-EBITDA 1.83
JAZZ's Debt-to-EBITDA is ranked lower than
52% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. JAZZ: 1.83 )
Ranked among companies with meaningful Debt-to-EBITDA only.
JAZZ' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.72  Med: 1.84 Max: 4.97
Current: 1.83
0.72
4.97
Interest Coverage 8.53
JAZZ's Interest Coverage is ranked lower than
90% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. JAZZ: 8.53 )
Ranked among companies with meaningful Interest Coverage only.
JAZZ' s Interest Coverage Range Over the Past 10 Years
Min: 0.7  Med: 9.01 Max: 76.32
Current: 8.53
0.7
76.32
Piotroski F-Score: 8
Altman Z-Score: 3.11
Beneish M-Score: -2.65
WACC vs ROIC
7.00%
15.43%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 34.78
JAZZ's Operating Margin % is ranked higher than
92% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. JAZZ: 34.78 )
Ranked among companies with meaningful Operating Margin % only.
JAZZ' s Operating Margin % Range Over the Past 10 Years
Min: 12.4  Med: 37.62 Max: 46.95
Current: 34.78
12.4
46.95
Net Margin % 23.64
JAZZ's Net Margin % is ranked higher than
91% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. JAZZ: 23.64 )
Ranked among companies with meaningful Net Margin % only.
JAZZ' s Net Margin % Range Over the Past 10 Years
Min: -5.32  Med: 24.83 Max: 49.25
Current: 23.64
-5.32
49.25
ROE % 15.79
JAZZ's ROE % is ranked higher than
91% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. JAZZ: 15.79 )
Ranked among companies with meaningful ROE % only.
JAZZ' s ROE % Range Over the Past 10 Years
Min: 4.38  Med: 21.72 Max: 111.92
Current: 15.79
4.38
111.92
ROA % 8.45
JAZZ's ROA % is ranked higher than
90% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. JAZZ: 8.45 )
Ranked among companies with meaningful ROA % only.
JAZZ' s ROA % Range Over the Past 10 Years
Min: -6.08  Med: 9.86 Max: 64.21
Current: 8.45
-6.08
64.21
ROC (Joel Greenblatt) % 218.65
JAZZ's ROC (Joel Greenblatt) % is ranked higher than
96% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. JAZZ: 218.65 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
JAZZ' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 218.65  Med: 630.91 Max: 11377.93
Current: 218.65
218.65
11377.93
3-Year Revenue Growth Rate 13.70
JAZZ's 3-Year Revenue Growth Rate is ranked higher than
68% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. JAZZ: 13.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
JAZZ' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -2.3  Med: 19.3 Max: 47.7
Current: 13.7
-2.3
47.7
3-Year EBITDA Growth Rate 11.60
JAZZ's 3-Year EBITDA Growth Rate is ranked higher than
77% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. JAZZ: 11.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
JAZZ' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 11.7 Max: 75.7
Current: 11.6
0
75.7
3-Year EPS without NRI Growth Rate 11.80
JAZZ's 3-Year EPS without NRI Growth Rate is ranked higher than
99% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. JAZZ: 11.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
JAZZ' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 6.4 Max: 104.6
Current: 11.8
0
104.6
GuruFocus has detected 2 Warning Signs with Jazz Pharmaceuticals PLC JAZZ.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» JAZZ's 30-Y Financials

Financials (Next Earnings Date: 2019-05-08)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2018

JAZZ Guru Trades in Q1 2018

Steven Cohen 50,000 sh (New)
Lee Ainslie 62,360 sh (+43.22%)
Ken Fisher Sold Out
Joel Greenblatt Sold Out
John Hussman Sold Out
Paul Tudor Jones Sold Out
Andreas Halvorsen 769,888 sh (-14.58%)
Jim Simons 958,400 sh (-23.01%)
Pioneer Investments 434,011 sh (-33.18%)
» More
Q2 2018

JAZZ Guru Trades in Q2 2018

Ronald Muhlenkamp 37,155 sh (New)
Paul Tudor Jones 1,474 sh (New)
Andreas Halvorsen 936,195 sh (+21.60%)
Lee Ainslie 41,910 sh (-32.79%)
Steven Cohen 35,000 sh (-30.00%)
Pioneer Investments 248,450 sh (-42.75%)
Jim Simons 832,800 sh (-13.11%)
» More
Q3 2018

JAZZ Guru Trades in Q3 2018

Joel Greenblatt 41,324 sh (New)
Jim Simons 895,794 sh (+7.56%)
Andreas Halvorsen 950,281 sh (+1.50%)
Pioneer Investments 3,401,000 sh (unchged)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Ronald Muhlenkamp 36,971 sh (-0.50%)
Pioneer Investments 223,763 sh (-9.94%)
Lee Ainslie 36,880 sh (-12.00%)
» More
Q4 2018

JAZZ Guru Trades in Q4 2018

John Hussman 20,400 sh (New)
Caxton Associates 1,823 sh (New)
Ken Heebner 330,000 sh (New)
Paul Tudor Jones 21,971 sh (New)
Jim Simons 1,150,201 sh (+28.40%)
Lee Ainslie 37,450 sh (+1.55%)
Pioneer Investments 371,182 sh (+65.88%)
Andreas Halvorsen 916,992 sh (-3.50%)
Joel Greenblatt 39,553 sh (-4.29%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:JAZZ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:BGNE, NAS:ALNY, NAS:BLUE, NAS:JUNO, NAS:SGEN, NAS:AVXS, NAS:NBIX, HKSE:02269, NAS:BIVV, NAS:ALKS, NAS:SAGE, NAS:EXEL, BOM:532523, HKSE:01548, OCSE:GEN, NAS:TECH, OSTO:SOBI, NAS:IONS, HKSE:01530, XKRX:215600 » details
Traded in other countries:J7Z.Germany,
Headquarter Location:Ireland
Jazz Pharmaceuticals PLC is a biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing differentiated products that address unmet medical needs.

Jazz Pharmaceuticals is an Ireland-domiciled specialty pharmaceutical firm focused primarily on treatments for orphan drug indications. Jazz's product portfolio includes lead drug Xyrem for narcolepsy, Erwinaze for acute lymphoblastic leukemia, Defitelio for severe veno-occlusive disease, and Vyxeos for acute myeloid leukemia.

Top Ranked Articles about Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals to Present at the Cowen and Company 39th Annual Healthcare Conference
Jazz Pharmaceuticals Announces Appointment of Anne O'Riordan to its Board of Directors
Jazz Pharmaceuticals to Report 2018 Fourth Quarter and Full Year Financial Results on February 26, 2019
Jazz Pharmaceuticals and Codiak BioSciences Announce Strategic Collaboration to Research, Develop and Commercialize Engineered Exosomes to Create Therapies for Hard-to-Treat Cancers
Jazz Pharmaceuticals Receives New PDUFA Goal Date for Solriamfetol for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
Jazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 7
Jazz Pharmaceuticals Announces Share Repurchase Program Authorization Increase of $400 Million
Report: Exploring Fundamental Drivers Behind Jazz Pharmaceuticals, 58, Encore Capital Group, Churchill Downs, Addus HomeCare, and Huntington Ingalls Industries — New Horizons, Emerging Trends, and Upcoming Developments
Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating JZP-258 for the Treatment of Idiopathic Hypersomnia
Jazz Pharmaceuticals to Highlight Hematology Research at ASH 2018 Annual Meeting

Ratios

vs
industry
vs
history
PE Ratio 18.48
JAZZ's PE Ratio is ranked higher than
54% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 28.79 vs. JAZZ: 18.48 )
Ranked among companies with meaningful PE Ratio only.
JAZZ' s PE Ratio Range Over the Past 10 Years
Min: 10.62  Med: 23.35 Max: 99999999.99
Current: 18.48
10.62
99999999.99
Forward PE Ratio 9.17
JAZZ's Forward PE Ratio is ranked higher than
79% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 28.41 vs. JAZZ: 9.17 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 18.48
JAZZ's PE Ratio without NRI is ranked higher than
54% of the 243 Companies
in the Global Biotechnology industry.

( Industry Median: 28.64 vs. JAZZ: 18.48 )
Ranked among companies with meaningful PE Ratio without NRI only.
JAZZ' s PE Ratio without NRI Range Over the Past 10 Years
Min: 11.75  Med: 23.26 Max: 99999999.99
Current: 18.48
11.75
99999999.99
Price-to-Owner-Earnings 17.58
JAZZ's Price-to-Owner-Earnings is ranked higher than
52% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 34.35 vs. JAZZ: 17.58 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
JAZZ' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.98  Med: 25.83 Max: 11068.13
Current: 17.58
8.98
11068.13
PB Ratio 2.95
JAZZ's PB Ratio is ranked higher than
54% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. JAZZ: 2.95 )
Ranked among companies with meaningful PB Ratio only.
JAZZ' s PB Ratio Range Over the Past 10 Years
Min: 2.54  Med: 4.64 Max: 32
Current: 2.95
2.54
32
PS Ratio 4.36
JAZZ's PS Ratio is ranked higher than
66% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. JAZZ: 4.36 )
Ranked among companies with meaningful PS Ratio only.
JAZZ' s PS Ratio Range Over the Past 10 Years
Min: 0.22  Med: 5.84 Max: 12
Current: 4.36
0.22
12
Price-to-Free-Cash-Flow 12.34
JAZZ's Price-to-Free-Cash-Flow is ranked higher than
68% of the 152 Companies
in the Global Biotechnology industry.

( Industry Median: 37.07 vs. JAZZ: 12.34 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
JAZZ' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.63  Med: 17.32 Max: 91.14
Current: 12.34
10.63
91.14
Price-to-Operating-Cash-Flow 10.31
JAZZ's Price-to-Operating-Cash-Flow is ranked higher than
78% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 29.99 vs. JAZZ: 10.31 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
JAZZ' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.88  Med: 15.15 Max: 55.81
Current: 10.31
8.88
55.81
EV-to-EBIT 12.93
JAZZ's EV-to-EBIT is ranked higher than
50% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. JAZZ: 12.93 )
Ranked among companies with meaningful EV-to-EBIT only.
JAZZ' s EV-to-EBIT Range Over the Past 10 Years
Min: -22.9  Med: 16.6 Max: 30.9
Current: 12.93
-22.9
30.9
EV-to-EBITDA 9.70
JAZZ's EV-to-EBITDA is ranked higher than
58% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. JAZZ: 9.70 )
Ranked among companies with meaningful EV-to-EBITDA only.
JAZZ' s EV-to-EBITDA Range Over the Past 10 Years
Min: -57.8  Med: 13.4 Max: 24.3
Current: 9.7
-57.8
24.3
EV-to-Revenue 4.50
JAZZ's EV-to-Revenue is ranked higher than
68% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. JAZZ: 4.50 )
Ranked among companies with meaningful EV-to-Revenue only.
JAZZ' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.5  Med: 6.3 Max: 11.9
Current: 4.5
1.5
11.9
PEG Ratio 1.30
JAZZ's PEG Ratio is ranked higher than
62% of the 115 Companies
in the Global Biotechnology industry.

( Industry Median: 2.02 vs. JAZZ: 1.30 )
Ranked among companies with meaningful PEG Ratio only.
JAZZ' s PEG Ratio Range Over the Past 10 Years
Min: 0.49  Med: 0.89 Max: 8.83
Current: 1.3
0.49
8.83
Shiller PE Ratio 32.56
JAZZ's Shiller PE Ratio is ranked lower than
65% of the 86 Companies
in the Global Biotechnology industry.

( Industry Median: 42.91 vs. JAZZ: 32.56 )
Ranked among companies with meaningful Shiller PE Ratio only.
JAZZ' s Shiller PE Ratio Range Over the Past 10 Years
Min: 28.07  Med: 60.08 Max: 908.5
Current: 32.56
28.07
908.5
Current Ratio 3.57
JAZZ's Current Ratio is ranked lower than
57% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. JAZZ: 3.57 )
Ranked among companies with meaningful Current Ratio only.
JAZZ' s Current Ratio Range Over the Past 10 Years
Min: 0.25  Med: 3.08 Max: 5.55
Current: 3.57
0.25
5.55
Quick Ratio 3.42
JAZZ's Quick Ratio is ranked lower than
55% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. JAZZ: 3.42 )
Ranked among companies with meaningful Quick Ratio only.
JAZZ' s Quick Ratio Range Over the Past 10 Years
Min: 0.23  Med: 3 Max: 5.46
Current: 3.42
0.23
5.46
Days Inventory 139.45
JAZZ's Days Inventory is ranked higher than
50% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 125.55 vs. JAZZ: 139.45 )
Ranked among companies with meaningful Days Inventory only.
JAZZ' s Days Inventory Range Over the Past 10 Years
Min: 70.82  Med: 106.32 Max: 155.54
Current: 139.45
70.82
155.54
Days Sales Outstanding 50.93
JAZZ's Days Sales Outstanding is ranked higher than
57% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. JAZZ: 50.93 )
Ranked among companies with meaningful Days Sales Outstanding only.
JAZZ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 34.99  Med: 50.74 Max: 58
Current: 50.93
34.99
58
Days Payable 121.93
JAZZ's Days Payable is ranked higher than
60% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: 63.91 vs. JAZZ: 121.93 )
Ranked among companies with meaningful Days Payable only.
JAZZ' s Days Payable Range Over the Past 10 Years
Min: 73.94  Med: 79.42 Max: 134.28
Current: 121.93
73.94
134.28

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.94
JAZZ's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
78% of the 193 Companies
in the Global Biotechnology industry.

( Industry Median: 3.12 vs. JAZZ: 0.94 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
JAZZ' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.87  Med: 2.21 Max: 77.26
Current: 0.94
0.87
77.26
Price-to-Median-PS-Value 0.75
JAZZ's Price-to-Median-PS-Value is ranked lower than
58% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. JAZZ: 0.75 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
JAZZ' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.13  Med: 0.83 Max: 1.53
Current: 0.75
0.13
1.53
Price-to-Peter-Lynch-Fair-Value 1.31
JAZZ's Price-to-Peter-Lynch-Fair-Value is ranked higher than
61% of the 64 Companies
in the Global Biotechnology industry.

( Industry Median: 1.72 vs. JAZZ: 1.31 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
JAZZ' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.68  Med: 1.08 Max: 7.7
Current: 1.31
0.68
7.7
Earnings Yield (Greenblatt) % 7.73
JAZZ's Earnings Yield (Greenblatt) % is ranked higher than
88% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. JAZZ: 7.73 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
JAZZ' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -175.5  Med: 5.6 Max: 10.9
Current: 7.73
-175.5
10.9
Forward Rate of Return (Yacktman) % 19.47
JAZZ's Forward Rate of Return (Yacktman) % is ranked higher than
90% of the 135 Companies
in the Global Biotechnology industry.

( Industry Median: 11.41 vs. JAZZ: 19.47 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
JAZZ' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -43.1  Med: 19.6 Max: 24.8
Current: 19.47
-43.1
24.8

More Statistics

Revenue (TTM) (Mil) $1,890.92
EPS (TTM) $ 7.28
Beta1.09
Volatility26.80%
52-Week Range $113.52 - 184.00
Shares Outstanding (Mil)57.06

Analyst Estimate

Dec19 Dec20 Dec21
Revenue (Mil $) 2,090 2,381 2,548
EBIT (Mil $) 641 918
EBITDA (Mil $) 1,035 1,296 1,467
EPS ($) 7.97 12.85 19.82
EPS without NRI ($) 7.97 12.85 19.82
EPS Growth Rate
(Future 3Y To 5Y Estimate)
7.63%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 88
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}